The Evolving Role of MET TKIs in NSCLC

The Evolving Role of MET TKIs in NSCLC

Identify effective testing modalities for biomarker assessment in non-small cell lung cancer (NSCLC) Summarize recent NSCLC trial results and recognize how they affect current clinical practice Identify new potential indications for MET inhibitors within NSCLC, such as a combination approach for EGFR TKI resistance Integrate guidelines, patient preferences, and treatment adherence into NSCLC treatment planning strategies

  • Provider:Global Learning Collaborative
  • Activity Link: https://reachmd.com/programs/17986
  • Start Date: 2024-10-01 05:00:00
  • End Date: 2024-10-01 05:00:00
  • Credit Details: AAPA Category 1 Credit™️: 0.75 hours
    AMA PRA Category 1 Credit™️: 0.75 hours
    Nursing: 0.75 hours
    Pharmacy: 0.75 hours
  • Commercial Support: No
  • Activity Type: Enduring Material
  • CME Finder Type: Online Learning
  • Fee to Participate: No, it's free
  • Measured Outcome: Learner Knowledge, Learner/Team Competence
  • Provider Ship: Directly Provided
  • Registration: Open to all
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.